Innocan’s SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union.

SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results. The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum.

Innocan’s SHIR™ Beauty & Science CBD Derma Cosmetics

To view an enhanced version of this graphic, please visit:

“As a Pharma Company, Innocan is committed to creating premium products that meet the highest quality standards to provide consumer confidence,” Iris Bincovich, co-founder and CEO of Innocan states. “Compliance with EU regulation is a major milestone for us, following the receipt of technical validation from the FDA for the marketing in the US of our over-the-counter Relief & Go Pain Relief spray, a few weeks ago. The next step is to initiate our various distribution platforms to deliver our SHIR™ CBD Derma Cosmetic line across the European Union and other markets where legally permitted to do so.”

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s